Aquaporin-4 water channel expression by thymoma of patients with and without myasthenia gravis

Journal of Neuroimmunology

Volumn 227, Issue 1-2, 2010, Pages 178-184

  Chan, K H ^a   Kwan, J S C ^a   Ho, P W L ^a   Ho, S L ^a   Chui, W H ^a   Chu, A C Y ^a   Ho, J W M ^a   Zhang, W Y ^a   Kung, M H W ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Aquaporin 4 autoantibodies; Aquaporin 4 water channel; Myasthenia gravis; Neuromyelitis optica; Paraneoplastic neurological disorders; Thymoma

Indexed keywords

AQUAPORIN 4; AQUAPORIN 4 ANTIBODY; AUTOANTIBODY; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; AQP4 PROTEIN, HUMAN;

ADULT; AGED; ANTIBODY ISOLATION; ANTIGEN BINDING; ARTICLE; CELL LYSATE; CELL MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; MALE; MOLECULAR WEIGHT; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYMOCYTE; THYMOMA; THYMUS SURGERY; WESTERN BLOTTING; BIOSYNTHESIS; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AQUAPORIN 4; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; THYMOMA; THYMUS NEOPLASMS;

EID: 77956650419     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.07.016     Document Type: Article

References (66)

1. Ami-Moghaddam M., Ottersen O.P. The molecular basis of water transport in the brain. Nat. Rev. Neurosci. 2003, 4:991-1001.
2. Ananth J., Davies R., Kerner B. Psychosis associated with thymoma. J. Nerv. Ment. Dis. 1984, 172:556-558.
3. Antoine J.C., Camdessanche J.P., Absi L., Lassabliere F., Feasson L. Devic disease and thymoma with anti-central nervous system and antithymus antibodies. Neurology 2004, 62:978-980.
4. Auguste K.I., Jin S., Uchida K., et al. Greatly impaired migration of implanted aquaporin-4-deficient astroglial cells in mouse brain toward a site of injury. FASEB J. 2007, 21:108-116.
5. Bichuetti D.B., de Barros T.M., Oliveira E.M.L., et al. Demyelinating disease in patients with myasthenia gravis. Arq. Neuropsiquiatr 2008, 66:5-7.
6. Bradl M., Misu T., Takahashi T., Watanabe M., Mader S., et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann. Neurol. 2009, 66:630-643.
7. Chan K.H., Lachance D.H., Harper C.M., Lennon V.A. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve 2007, 36:651-658.
8. Chan K.H., Pittock S.J., Lennon V.A. Coexisiting autoimmune channelopathies: neuromyelitis optica with myasthenia gravis. Neurology 2008, 70:A236. (Abstract).
9. Chan K.H., Ramsden D.B., Yu Y.L., et al. NMO-IgG in idiopathic inflammatory demyelinating disorders among Hong Kong Chinese. Eur. J. Neurol. 2009, 16:310-316.
10. Cheuk W., Tsang W.Y., Chan J.K. Microthymoma: definition of the entity and distinction from nodular hyperplasia of the thymic epithelium (so-called microscopic thymoma). Am. J. Surg. Pathol. 2005, 29(3):415-419.
11. Cree B.A.C., Goodin D.S., Hauser S.L. Neuromyelitis optica. Semin. Neurol. 2002, 22:105-122.
12. Cree B.A., Lamb S., Morgan K., Chen A., Waubant E., Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005, 64:1270-1272.
13. de Seze J., et al. Devic's neuromyelitis: clinical, laboratory, MRI and outcome profile. J. Neurol. Sci. 2002, 197:57-61.
14. Devic E. Myelite subaigue compliquee de nevrite optique. Bull. Med. (Paris) 1894, 8:1033-1034.
15. Evoli A., MMinicuci G.M., Vitaliani R., Battaglia A., Marca G.D., Lauriola L., Fattorossi A. Paraneoplastic diseases associated with thymoma. J. Neurol. 2007, 254:756-762.
16. Frigeri A., Gropper M.A., Umenishi F., Kawashima M., Brown D., Verkman A.S. Localization of MIWC and GLIP water channel homologs in neuromuscular, epithelial and glandular tissues. J. Cell Sci. 1995, 108:2993-3002.
17. Furukawa Y., Yoshikawa H., Yachie A., Yamada M. Neuromyelitis optica associated with myasthenia gravis: characteristic phenotype in Japanese population. Eur. J. Neurol. 2006, 13:655-658.
18. Gerli R., Paganelli R., Cossarizza, et al. Long-term immunologic effects of thymectomy in patients with myasthenia gravis. J. Allergy Clin. Immunol. 1999, 103:865-872.
19. Ghezzi A., Bergamaschi R., Martinelli V., et al. Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. J. Neurol. 2004, 251:47-52.
20. Hinson S.R., Pittock S.J., Lucchinetti C.F., Roemer S.F., Fryer J.P., et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007, 69:1-11.
21. Hiroaki Y., Tani K., Kamegawa A., et al. Implications of the aquaporin-4 structure on array formation and cell adhesion. J. Mol. Biol. 2006, 355:628-639.
22. Hu J., Verkman A.S. Increased migration and metastatic potential of tumor cells expressing aquaporin water channels. FASEB J. 2006, 20:1892-1894.
23. Jablonski E.M., Webb A.N., McConnell A.M., Riley M.C., Hughes F.M. Plasma membrane aquaporin activity can affect the rate of apoptosis but is inhibited after apoptotic volume decrease. Am. J. Physiol. Cell Physiol. 2004, 286:C975-C985.
24. Jacob A., Weinshenker B.G., Violich I., McLinskey N., Krupp L., et al. Treatment of neuromyelitis optica with rituximab. Retrospective analysis of 25 patients. Arch. Neurol. 2008, 65(11):1443-1448.
25. Jarius S., Franciotta D., Bergamaschi R., Wright H., Littleton E., Palace J., Hohlfeld R., Vincent A. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007, 68:1076-1077.
26. Jung J.S., Bhat R.V., Preston G.M., Guggino W.B., Baraban J.M., Agre P. Molecular characterization of an aquaporin cDNA from brain: candidate osmoreceptor and regulator of water balance. Proc. Natl. Acad. Sci. USA 1994, 91:13052-13056.
27. Kinoshita M., Nakatsuji Y., Moriya M., Okuno T., Kumanogoh A., et al. Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. NeuroReport 2009, 20:508-512.
28. Kinoshita M., Nakatsuji Y., Kimura T., Moriya M., Takata T., et al. Neuromyelitis optica: passive transfer to rats by human immunoglobulin. Biochem. Biophys. Res. Commun. 2009, 386:623-627.
29. Kister I., Gulati S., Boz C., et al. Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch. Neurol. 2006, 63:851-856.
30. Lee E.K., Maselli R.A., Ellis W.G., Agius M.A. Morvan's fibrillary chorea: a paraneoplastic manifestation of thymoma. J. Neurol. Neurosurg. Psychiatry 1998, 65:857-862.
31. Lennon V.A. Serological profile of myasthenia gravis and distinction from the Lambert-Eaton myasthenic syndrome. Neurology 1997, 48(Supp 5):S23-S27.
32. Lennon V.A., Wingerchuk D.M., Kryzer T.J., et al. A serum autoantibody marker of neuromyelitis optica. Lancet 2004, 364:2106-2112.
33. Lennon V.A., Kryzer T.J., Pittock S.J., et al. IgG marker of optic-spinal multiple sclerosis binds to aquaporin-4 water channel. J. Exp. Med. 2005, 202:473-477.
34. Lucchinetti C.F., Mandler R.N., McGavern D., et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002, 125:1450-1461.
35. Mandler R.N., Ahmed W., Dencoff J.E. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998, 51:1219-1220.
36. McCoy E., Sontheimer H. Expression and function of water channels (aquaporins) in migrating malignant astrocytes. Glia 2007, 55(10):1034-1043.
37. McKeon A., Lennon V.A., Jacob A., Matiello M., Lucchinetti C.F., Kale N., Chan K.H., Weinshenker B.G., Apiwattinakul M., Wingerchuk D.M., Pittock S.J. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 2009, 39(1):87-90.
38. Misu T., Fujihara K., Nakamura M., et al. Loss of aquaporin-4 active in active perivascular lesions in neuromyelitis optica: a case report. Tohoku J. Exp. Med. 2006, 209:269-275.
39. Mori T., Nomori H., Ikeda K., Kobayashi H., Iwatani K., Yoshioka M., Iyama K. Microscopic-sized "microthymoma" in patients with myasthenia gravis. Chest 2007, 131(3):847-849.
40. Mueller S., Dubal D.B., Josephson S.A. A case of paraneoplastic myelopathy associated with the neuromyelitis optica antibody. Nat. Clin. Pract. Neurol. 2008, 4:284-288.
41. Nakashima I., Fujihara K., Miyazawa I., et al. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J. Neurol. Neurosurg. Psychiatry 2006, 77:1073-1075.
42. Neely J.D., Christensen B.M., Nielsen S., Agre P. Heterotetrameric composition of aquaporin-4 water channels. Biochemistry 1999, 38:11156-11163.
43. Ng W.H., Hy J.W., Tan W.L., Liew D., Lim T., et al. Aquaporin-4 expression is increased in edematous meningiomas. J. Clin. Neurosci. 2009, 16:441-443.
44. Nicchia G.P., Nico B., Camassa L.M.A., et al. The role of aquaporin-4 in the blood-brain barrier development and integrity: studies in animal and cell culture models. Neuroscience 2004, 129:935-945.
45. Nico B., Frigeri A., Nicchia G.P., et al. Role of aquaporin-4 water channel in the development and integrity of the blood-brain barrier. J. Cell Sci. 2001, 114:1297.
46. Oopik M., Puksa L., Luus S.M., Kaasik A.E., Jakobsen J. Clinical and laboratory-reconfirmed myasthenia gravis: a population-based study. Eur. J. Neurol. 2008, 15:246-252.
47. Papadopoulos M.C., Saadoun S., Verkman A.S. Aquaporins and cell migration. Eur. J. Physiol. 2008, 456:693-700.
48. Phillips L.H. The epidemiology of myasthenia gravis. Semin. Neurol. 2004, 24:17-20.
49. Pittock S., Lennon V.A. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch. Neurol. 2008, 65:629-632.
50. Pittock S.J., Lennon V.A., De Seze J., et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch. Neurol. 2008, 65:78-83.
51. Roemer S.F., Parisi J.E., Lennon V.A., Benarroch E.E., Lassmann H., Bruck W., et al. Pattern specific loss of aquaporin-4 immunoreactivity distinguish neuromyelitis optical from multiple sclerosis. Brain 2007, 130(5):1194-1205.
52. Saadoun S., Papadopoulos M.C., Davis D.C., Krishna S., Bell B.A. Aquaporin-4 expression is increased in oedematous human brain tumours. J. Neurol. Neurosurg. Psychiatry 2002, 72:262-265.
53. Sabater L., Giralt A., Boronat A., Hankiewicz K., Blanco Y., Llufriu S., Alberch J., Graus F., Saiz A. Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study. J. Neuroimmunol. 2009, 215:31-35.
54. Silberstein C., Bouley R., Huang Y., Fang P., Pastor-Soler N., Brown D., Van Hoek A.N. Membrane organization and function of M1 and M23 isoforms of aquaporin-4 in epithelial cells. Am. J. Physiol. Renal Physiol. 2004, 287:F501-F511.
55. Sinclair C., Kirk J., Herron B., Fitzgerald U., McQuaid S. Absence of aquaporin 4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal-appearing white matter. Acta Neuropathol. 2007, 113:187-194.
56. Strand L., Moe S.E., Solbu T.T., Vaadal M., Holen T. Roles of aquaporin-4 isoforms and amino acids in square array assembly. Biochemistry 2009, 48:5785-5793.
57. Takahashi T., Fujihara K., Nakashima I., Misu T., Miyazawa I., et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007, 130:1235-1243.
58. Uzawa A., Mori M., Iwai Y., Kobayashi M., Hayakawa S., et al. Association of anti-aquaporin-4 antibody-positive neuromyelitis optica with myasthenia gravis. J. Neurol. Sci. 2009, 287(1-2):105-107.
59. Verkman A.S. Mammalian aquaporins: diverse physiological roles and potential significance. Expert Rev. Mol. Med. 2008, 10:1-18.
60. Verkman A.S., Hara-Chikuma M., Papadopoulos M.C. Aquaporins - new players on cancer biology. J. Mol. Med. 2008, 86:523-529.
61. Vincent A., Palace J., Hilton-Jones D. Myasthenia gravis. Lancet 2001, 68:2122-2128.
62. Vincent T., Saikali P., Cayrol R., Roth A.D., Bar-Or A., Prat A., Antel J.P. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J. Immunol. 2008, 181:5730-5737.
63. Voltz R. Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. Lancet Neurol. 2002, 1:294-305.
64. Wingerchuk D.M., Hogancamp W.F., O'Brien P.C., Weinshenker B.G. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999, 53:1107-1114.
65. Wingerchuk D.M., Lennon V.A., Lucchinetti C.F., Pittock S.J., Weinshenker B.G. The spectrum of neuromyelitis optica. Lancet Neurol. 2007, 6:805-815.
66. Yu Z., Kryzer T.J., Griesmann G.E., et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann. Neurol. 2001, 49:146-154.